Quick Answer
VYNE Therapeutics Inc. reported Net Income Loss of -$26.48 million for the year ending 2025.
- VYNE Therapeutics Inc. showed an increase of +33.5% in Net Income Loss from 2024 to 2025.
- This data is from VYNE Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), VYNE Therapeutics Inc.'s Net Income Loss has declined by 474.7%.
- Historical annual values: Fiscal year 2025: -$26.48 million | Fiscal year 2024: -$39.83 million | Fiscal year 2023: -$28.45 million | Fiscal year 2022: -$23.21 million | Fiscal year 2021: -$73.33 million | Fiscal year 2020: -$255.57 million | Fiscal year 2019: -$95.18 million | Fiscal year 2018: -$74.16 million | Fiscal year 2017: -$29.08 million | Fiscal year 2016: -$14.07 million | Fiscal year 2015: -$4.61 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: